Submit Manuscript  

Article Details


The Potential Clinical Value of Curcumin and its Derivatives in Colorectal Cancer

[ Vol. 21 , Issue. 13 ]

Author(s):

Zhaoying Yao, Thi Ha Le, Qianming Du, Huiwen Mu, Chao Liu* and Yubing Zhu*   Pages 1626 - 1637 ( 12 )

Abstract:


Background: Curcumin, a naturally occurring polyphenol, possesses pleiotropic pharmacologic properties, including anti-inflammatory and anti-oxidant activities. Epidemiological evidence suggests that curcumin intake is associated with a reduced risk of colorectal cancer (CRC), highlighting the enormous potential of this botanical agent in the prevention and treatment of CRC.

Objective: We summarize the anticancer activity of curcumin and its derivatives in CRC.

Methods´╝ÜWe conducted a literature review on the therapeutic effects of curcumin and its derivatives in CRC.

Results: In this review, a summary of the activities of curcumin in the treatment of CRC regarding its bioavailability, anticancer activity, modes of action, curcumin delivery systems have been provided based on the researches from preclinical experiments. Also, we discuss the therapeutic effects of curcumin derivatives in CRC. The human clinical trials that used curcumin or curcumin derivatives for the treatment of CRC are also highlighted here.

Conclusion: Curcumin possesses great potential as a chemopreventive agent in CRC. Moreover, emerging evidence reveals that it can be an effective adjuvant to CRC therapy. To date, few studies have explored the anticolon cancer activity of curcumin formulation and curcumin derivatives in vivo; therefore, more works are needed to confirm their effectiveness. In clinical trials, curcumin treatment protocols (formulation, dose, and duration) vary among studies. However, these trials consistently point out that the compound is well-tolerated and safe, albeit with little consensus on its therapeutic efficacy.

Keywords:

Curcumin, colorectal cancer, chemotherapy, chemoprevention, adjunct, therapeutic efficacy

Affiliation:

Department of Clinical Pharmacy, School of Basic Medicine &Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Rd., Shanghai 200240, General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Department of Clinical Pharmacy, School of Basic Medicine &Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, Department of Pharmacy, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Department of Clinical Pharmacy, School of Basic Medicine &Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009



Read Full-Text article